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Vascular Endothelial Growth Factor and Fibroblast Growth
Factor-2 Incorporation in Starch-Based Bone
Tissue-Engineered Constructs Promote the In Vivo
Expression of Neovascularization Mediators
Tı´rcia C. Santos, PhD,1–3 Tatjana J. Morton, PhD,3 Martina Moritz, MD,3 Sabine Pfeifer,3 Kathrin Reise, MD,3
Alexandra P. Marques, PhD,1,2 Anto´nio G. Castro, PhD,2,4 Rui L. Reis, PhD,1,2 and Martijn van Griensven, PhD3,5
The ideal bone tissue-engineered (TE) construct remains to be found, although daily discoveries significantly
contribute to improvements in the field and certainly have valuable long-term outcomes. In this work, different
TE elements, aiming at bone TE applications, were assembled and its effect on the expression of several vas-
cularization/angiogenesis mediators analyzed. Starch/polycaprolactone (SPCL) scaffolds, obtained by two
different methodologies, were combined with fibrin sealant (Baxter), human adipose-derived stem cells
(hASCs), and growth factors (vascular endothelial growth factor [VEGF] or fibroblast growth factor-2 [FGF-2]),
and implanted in vascular endothelial growth factor receptor-2 (VEGFR2)-luc transgenic mice. The expression
of VEGFR2 along the implantation of the designed constructs was followed using a luminescence device
(Xenogen) and after 2 weeks, the explants were retrieved to perform histological analysis and reverse
transcriptase–polymerase chain reaction for vascularization (VEGF and VEGFR1) and inflammatory (tumor
necrosis factor-alpha, interleukin-4, and interferon-gamma) markers. It was showed that SPCL scaffolds ob-
tained by wet spinning and by fiber bonding constitute an adequate support for hASCs. The assembled TE
constructs composed by fibrin sealant, hASCs, VEGF, and FGF-2 induce only a mild inflammatory reaction after
2 weeks of implantation. Additionally, the release of VEGF and FGF-2 from the constructs enhanced the ex-
pression of VEGFR2 and other important mediators in neovascularization (VEGF and VEGFR1). These results
indicate the potential of VEGF or FGF-2 within a bone TE construct composed by wet-spun SPCL, fibrin sealant,
and hASCs in promoting the vascularization of newly formed tissue.
Introduction
The field of tissue engineering has achieved severalsuccesses within the recent past.1,2 Different biomateri-
als, cells, growth factors, and stimulation conditions, as well
as numerous combinations among them have been proposed
by several research groups as potential routes to assemble
the perfect bone tissue-engineered (TE) construct.3–8 Despite
this, in bone tissue engineering, vascularization remains a
fairly large concern, not yet perfectly addressed. Besides the
well-known fact that the bone is extremely dependent on a
vascular network, which provides nutrients, minerals, and
oxygen essential for cell survival,9 angiogenesis was shown
to play a key role, not only in bone growth,9 but also in bone
healing10 and consequently in bone tissue regeneration.
Numerous strategies4,11–13 have therefore, emerged as a need
to achieve the vascularization of bone-engineered constructs
within a reasonable time, which contributes to attain func-
tional tissue substitutes.
Noteworthy, works have been showing that endothelial
cells, either in single culture or cocultured with primary
osteoblasts or stem cells, in 3D structures lead to the for-
mation of vascular-like structures in vitro14,15 and improves
vascularization in vivo.11,16–18 Nevertheless, despite the de-
velopments in cell isolation and culture technologies, the
variability of cell sources, as well as in culture conditions
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among the different studies is still a major issue and might
jeopardize some of the conclusions drawn.
A valuable alternative to tackle the vascularization of bone
TE constructs relies on the incorporation in the construct of
important mediators, such as vascular endothelial growth
factor (VEGF)5,17–20 and fibroblast growth factor (FGF),21,22
that can be controlled and released from the scaffolding
material. In fact, the incorporation of VEGF and subsequent
release has been achieved with microspheres,20 hydro-
gels,21,22 and 3D scaffolds.17 For all these systems, VEGF
release showed to promote in vitro and in vivo vasculariza-
tion.17,20 In the same context, FGF-2 showed increased in vivo
neovascularization after being released from a chitosan/
heparinoid hydrogel after subcutaneous implantation.21,22 A
combined approach, VEGF plus FGF incorporated into
chitosan hydrogels was also attempted with confirmed re-
lease of both growth factors within the first day and with a
significant stimulation of human umbilical vein endothelial
cells.23 An uncertain issue is, however, the degradation rate
of the carriers and subsequently the release profile and doses
of the loaded factors which, if not controlled, might induce
an unexpected reaction.23 Considering this, a different cell-
based strategy aiming at targeting not only the vasculariza-
tion but also the regeneration of a vascularized tissue as
bone, has been also proposed.6,11 The differentiation poten-
tial of several mesenchymal stem cells has been taken into
consideration when cell-seeded matrices are transplanted
into several in vivo regeneration models expecting that the
undifferentiated cells either undergo a commitment into the
lineages of interest4,18 or significantly contribute to signaling
host progenitor cells.16
In this work, it was hypothesized that the assembly of a
complex TE construct, comprehending a well-studied starch-
based scaffold (starch/polycaprolactone [SPCL])3,8,24 and fi-
brin glue,25 human adipose-derived stem cells (hASCs)26 and
key growth factors (VEGF and FGF-2),27,28 would induce the
vascularization of the construct. Taking into consideration
the features of the mentioned cells, growth factors, and
materials used in the last years of investigation in tissue
engineering, it was expected to achieve a deeper knowledge
on the effect of each one of those elements on the expression
of vascular endothelial growth factor receptor-2 (VEGFR2)
and other molecular mediators of neovascularization. In fu-
ture work, these scaffolds could be used for bone engineering
purposes as this material has been shown to be suitable for
that.29,30
Materials and Methods
Isolation of ASC
Liposuction material was collected from 3 female donors
(43–48 years old) and was approved by the local ethics
board. Isolation of ASC was performed as described else-
where.31 Briefly, adipose tissue was washed with a phos-
phate-buffered saline to remove most of the blood and
tumescence solution. Subsequently, tissue was digested with
collagenase (Biochrom) at 37C for 1 h. To eliminate red
blood cells, the isolated fraction was incubated with a
erythrocyte lysis buffer for 10min. Remaining cells were
filtered through a 100 mm filter and cultured in expansion
medium. During the first 1 to 2 passages, 2D cultures were
subjected to an endothelial growth medium (EGM-2; Lonza)
which is already described to support rapid expansion and
multipotency of ASCs.32
Transfection of the ASCs
To trace the hASCs after implantation, cells were prior
transfected with a luciferase plasmid using Lipofecta-
mine2000 (Invitrogen).33 Cell transfection was carried
out according to the manufacturer’s recommendations.
Briefly, luciferase DNA (plasmid) and lipofectamine were
separately diluted in 50mL of Ham’s F-12 cell culture me-
dium (Sigma-Aldrich), without fetal calf serum (FCS), com-
plemented with 1% L-glutamine, and antibiotics (basal
medium), and gently mixed. The two solutions were mixed
and incubated for 20min at room temperature to allow the
formation of lipo-complexes. After the incubation period, the
mixture was added to the cells in culture and left for 4 h after
which the medium was changed to a fresh basal medium.
The cells were ready to be used *20 h after the transfection
procedure.
The transfection efficiency is 40%–60%, as has been de-
scribed in Wolbank et al.33 On the cellular level the expres-
sion can be detected for 3 weeks, but the percentage of
positive cells decreases over time in vitro independent of the
chosen culture conditions. After 2 weeks, around 25% of the
initial expression remains visible and positive cells remain
detectable even after 3 weeks of culture.
Starch-based scaffolds production
Starch-based scaffolds were produced from a blend of
starch with poly-e-caprolactone (30:70%) (SPCL), by two
different methodologies described elsewhere: wet-spinning
(SPCL-WS)8 and fiber-bonding (SPCL-FB).3 Briefly, for the
production of SPCL-WS scaffolds, the polymer was dis-
solved in chloroform at a concentration of 40% (w/v) to
obtain a polymer solution with proper viscosity. The poly-
mer solution was loaded into a syringe, placed in a syringe
pump (World Precision Instruments), and the solution was
subsequently extruded into a methanol coagulation solu-
tion. With this methodology, scaffolds composed of fibers
of 100 mm diameter and with around 77% porosity are ob-
tained.8 The fiber mesh structure was formed during the
processing by the random movement of the precipitation
container. The formed scaffolds were then dried overnight
at room temperature to allow any remaining solvents to
evaporate. For the fabrication of the SPCL-FB scaffolds, fiber-
meshes previously obtained by a meltspinning methodology
were placed in a glass mould and heated in an oven at 150C.
Immediately after removing the moulds from the oven, the
fibers were slightly compressed by a Teflon cylinder and
then cooled at - 15C.3 This procedure creates scaffolds of
around 75% diameter with fibers ranging from 120 to 500 mm
diameter.3 All samples were cut into discs of 5mm diameter
and *1mm thickness and sterilized by a standard proce-
dure with ethylene oxide.34
Assembly of the TE constructs
For the cell tracking experiments, the two types of SPCL
scaffolds were seeded with the transfected hASCs in a con-
centration of 1.33 · 104 cells/scaffold in basal medium sup-
plemented with 10% FCS and 1% antibiotics (penicillin/
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streptomycin), and incubated for 24 h at 37C and 5% CO2 in
a humidified environment. Using hASCs in mice is not
contraindicated, as these cells have been shown to be im-
munoprivileged and have immunosuppressive properties.31
The assembling of the TE constructs to implant in the
VEGFR2 transgenic mice was performed as follows: each
type of SPCL scaffold was mixed with the 2.0mL two-
component FS Tisseel VH (Baxter AG), growth factors (VEGF
and FGF-2), and hASCs. The sealer protein component
(fibrinogen 75–115mg/mL) was reconstituted with a fibri-
nolysis inhibitor solution (Aprotinin 3000 KIU/mL) and
spiked either with VEGF (200 ng/mL) or FGF-2 (200 ng/mL).
The thrombin component (500 IU/mL) was reconstituted
with CaCl2 (40-mmol/mL) and diluted to 4 IU/mL.
35 Scaf-
folds, cells (1.5 · 104 cells/scaffold/50 mL), and growth fac-
tors, which were added to the fibrinogen component, were
then mixed with the thrombin component (1:1), in a total
volume of 75 mL, at 37C. The clot was allowed to form for
15min, at 37C and 5% CO2 after which 300mL of cell culture
medium was added. Constructs were kept overnight at
37C and 5% CO2.
In vivo implantation
Nude mice. All the animal experiments were previously
approved by the local ethics authorities. The in vivo fate of
the in vitro transfected hASCs seeded onto SPCL scaffolds
was followed in nude mice. Thirteen female Balb/c nu/nu
nude mice, with an average weight of 21.6 – 1.2 g were used;
six animals to implant the SPCL-WS scaffolds, six animals to
implant the SPCL-FB scaffolds, and one animal as control.
All surgical procedures were performed under sterile con-
ditions in a vertical laminar flow hood. Each animal was
intraperitoneally (i.p.) anaesthetized with ketamine (60mg/
kg) and xylazine (7.5mg/kg). Subsequently, the skin of the
mice was disinfected with betaisodona and two lateral inci-
sions of *0.5 cm, containing the subcutis and panniculus
carnosus, were performed in the back of the animals. Two
caudal-latera- oriented pockets were created in each animal
by blunt dissection, where the TE constructs with the trans-
fected ASCs were inserted. After implantation, the panni-
culus carnosus and the skin of the animals were carefully
sutured. The bioluminescence signal, from the in vivo lucif-
erase activity that identifies the location of the transfected
cells, was quantified (emitted photon counts per second)
using the Live Image Software (Xenogen). Specific areas for
the signal detection, considering the original location of the
implants and possible migration of the cells from the con-
structs, were predetermined (Fig. 1A); I and II correspond to
the left and right implant sites, III corresponds to the dorsum
of the animals, the most probable migration localization.
Bioluminescence images were collected immediately after
surgery and on days 1, 3, 6, 9, and 13. The luciferase activity
was measured 15min after luciferin subcutaneous injection
and normalized to the respective areas for further graphical
representation.
Transgenic mice. Thirty-eight FVB/N-Tg(VEGF-r2–luc)
Xen mice (VEGFR2-LUC),36 with an average weight of
33.8 – 3.6 g were used to assess the effect of the addition of
VEGF, FGF-2, hASCs, or fibrin sealant to the SPCL scaf-
folds for vascularization. These mice carry a transgene
FIG. 1. (A) Schematic representation of a nudemousewith the
areas considered for the capture of the luminescence signal
emitted by the transfected cells seeded on the SPCL-based scaf-
folds: I and II correspond to the implantation sites; III corresponds
to the dorsum (back) of the animals to where the cells eventually
migrate. (B) Graphical representation of the luminescence signal
detected in the different areas, on the SPCL-WS and SPCL-FB
implanted nude mice. SPCL, starch/polycaprolactone; SPCL-
WS, SPCL-wet spinning; SPCL-FB, SPCL-fiber-bonding.
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that contains a 4.5 kb murine VEGFR2 promoter fragment
that drives the expression of a firefly luciferase reporter
protein.36
Six test groups were established per type of scaffold
(Table 1): (a) untreated control to measure endogenous
expression of VEFGR2 due to surgical procedure; (b) scaf-
fold group to measure expression of VEFGR2 due to scaf-
fold implantation (SPCL-WS and SPCL-FB); (c) scaffold
plus FS to measure the expression of VEGFR2 due to the
use of FS (SPCL-WS + FS and SPCL-FB + FS); (d) scaffold
plus FS and hASCs group, to measure the expression of
VEGFR2 due to the presence of hASCs (SPCL-WS + FS +
hASCs and SPCL-FB + FS + hASCs); (e) scaffold plus FS,
hASCs and VEGF (200 ng/mL) to measure the expression
of VEGFR2 induced by the VEGF delivery (SPCL-WS +
FS + hASCs +VEGF and SPCL-FB + FS + hASCs +VEGF);
and (f) scaffold plus FS, ASCs and FGF-2 (200 ng/mL), to
measure the expression of VEGFR2 induced by the FGF-2
delivery (SPCL-WS + FS + hASCs + FGF-2 and SPCL-FB +
FS + hASCs + FGF-2).
Each animal was anaesthetized using 3% isoflurane for
induction and maintaining with an i.p. injection of ketamine
(60mg/kg) and xylazine (7.5mg/kg). Mice were injected
subcutaneously with luciferin (150mg/kg) and imaged with
the in vivo imaging system (VivoVisions IVISs; Xenogen) to
acquire the background image signal corresponding to the
presurgical activity, set to 100%. Specific areas for the bio-
luminescence detection were established (Fig. 2A); I corre-
sponds to the incision area; II and III correspond to the left
and right implant sites (pockets). The signal detected at the
incision site correlates with the expression of the VEGFR2
gene with the ongoing inflammatory process as the incision
heals. Each animal’s dorsum was then shaved and disin-
fected, and a 1 cm incision at the caudal aspect of the neck
was made. For the subcutaneous implantation, a caudal
lateral access to each flank was bluntly subcutaneously cre-
ated through this incision, forming two pockets per animal.
Into each pocket, the construct was inserted accordingly to
the different test groups. Subsequent measurements in the
predetermined areas were referenced to the presurgical
baseline and obtained immediately after surgery and on days
3, 6, 9, and 13 after implantation, as well as 15min after
luciferin injection.
Ex vivo analysis
At the end of the observation (2 weeks), each animal
was i.p. anaesthetized and subsequently sacrificed with an
intracardial overdose of ketamine (60mg/kg) and xylazine
(7.5mg/kg). The scaffolds and surrounding tissue were ex-
planted and, half of the sample was fixed in 3.7% formalin
for histological analysis, and the other half was snap-frozen
for molecular biology evaluation. Histology was performed
according to existing standard protocols for haematoxylin
and eosin staining. The angiogenic index of each lesion
was determined based on microvessel count (MVC), which is
the mean number of microvessels in five areas of highest
vascular density at 200· magnification, as described by
Maeda et al.37
Samples for vWF antibody were pretreated with protein-
ase K (Dako) for 10min. Then all samples (n= 6 histologies
were analysed per group) were treated with peroxide (1.5%
H2O2 in Tris-buffered saline) for 30min at room temperature
to deactivate endogenous peroxidase activity. After rinsing
with a TRIS-buffered saline for 10min, sections were incu-
bated with 2.5% horse serum (Vector Laboratories). There-
after, tissue sections were incubated with the primary vWF
antibody (polyclonal rabbit anti-human; Dako) or primary
CD31 antibody (rabbit anti-CD31; Santa Cruz) over night at
4C and then washed with the TRIS-buffered saline. Imm-
PRESS anti-rabbit micropolymers (Vector Laboratories) were
then added and incubated for 30min at room temperature.
After washing, staining was performed by diaminobenzidine
(Sigma Aldrich) for 6min. The slides were then counter-
stained with hematoxylin, dehydrated, and mounted per-
manently with Roti-Histokit II (Carl Roth).
Table 1. Distribution of the Test Groups
for the In Vivo Implantation on the Transgenic
FVB/N-Tg(VEGF-r2–luc)Xen Mice
Group Condition
a Control–subcutaneous pockets without any implant
b SPCL-WS SPCL-FB
c SPCL-WS+ FS SPCL-FB + FS
d SPCL-WS+ FS +hASCs SPCL-FB + FS +hASCs
e SPCL-WS+ FS +
hASCs +VEGF
SPCL-FB + FS +
hASCs +VEGF
f SPCL-WS+ FS +
hASCs + FGF
SPCL-FB + FS +
hASCs + FGF
SPCL, starch/polycaprolactone; SPCL-FB, SPCL-fiber-bonding;
SPCL-WS, SPCL-wet spinning; hASCs, human adipose-derived stem
cells; VEGF, vascular endothelial growth factor; FGF, fibroblast
growth factor.
FIG. 2. (A) Schematic representation of a transgenic
VEGFR2-LUC mouse with the areas considered for the
capture of the luminescence signal emitted by the transfected
cells seeded on the SPCL-based TE constructs: I corresponds
to incision area; II and III correspond to the left and right
implant sites (pockets). (B) Graphical representation of the
luminescence signal detected in the different areas, on the
SPCL-WS assembled constructs. (C) Graphical represen-
tation of the luminescence signal detected in the different
areas, on the SPCL-FB assembled constructs. TE, tissue-
engineered; VEGFR2, vascular endothelial growth factor
receptor.
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Molecular biology was evaluated by reverse transcriptase–
polymerase chain reaction (RT-PCR) to detect the expression
of vascularization and inflammation (Table 2).
Statistical analysis
Mean values and standard deviations are reported for the
luminescence signal measurements38 and represented
graphically. Data were analyzed by a single factor analysis of
variance test and the significance value was set at p < 0.05.
Statistical analysis was performed among the different test
groups for the determined time points and, along the total
implantation time period, between two followed time points
in each tested condition using multiple analysis of variance
after having tested for normal distribution. To correct for
multiple testing error, a Bonferroni correction was applied.
Additionally, the postimplantation time point was compared
with the end time point of observation.
Results
In vivo ASCs tracking
The luminescence emitted by the transfected cells was
detected with the in vivo imaging system (VivoVisions IVISs;
Xenogen), acquired with the Live Image Software (Xenogen)
and recorded as emitted photon counts per second.
Before the in vivo implantation of the TE constructs, a
SPCL scaffold seeded with the transfected hASC for 24 h,
was placed into the dark chamber of the Xenogen equipment
to confirm the presence of luminescence-emitting cells on the
scaffolds (data not shown).
FIG. 2. (Continued).
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The signal emitted from the transfected cells was similar in
both types of SPCL scaffolds, and the peak of emitted signal
was detected on day 6 after implantation (Fig. 1B). For both
SCPL-WS and for SPCL-FB scaffolds, the luminescence sig-
nal starts to increase from day 2 onward, reaching the
maximum value at day 6 and decreases from this day until
the end point of the experiment, 13 days (Fig. 1B). Never-
theless, for the control condition, to which two pockets were
created without any implantation, the signal was similar to
the luminescence emitted by the transfected hASCs seeded
on the SPCL-based scaffolds (Fig. 1). The signal at the inci-
sion sites was therefore, not taken into consideration for
migration purposes.
The transfected cells seemed to migrate from the scaffolds
very early, as can be observed by the significantly high signal
( p < 0.05) detected in the dorsum of the mice implanted with
the SPCL-WS and with the SPCL-FB constructs (Fig. 1B).
However, the kinetics of the emitted signal, during the
FIG. 2. (Continued).
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implantation time, were similar for the implant sites and the
dorsum of the animals (Fig. 1B).
In vivo induced neovascularization potential
VEGFR2 expression. After the assembly of the TE con-
structs combining the starch-based scaffolds, hASCs, fibrin
sealant, and growth factors (VEGF or FGF-2), the constructs
were subcutaneously implanted in the back of transgenic
VEGFR2-LUC mice. The emitted luminescence was detected
with the in vivo imaging system (VivoVisions IVISs; Xeno-
gen) and acquired with the Live Image Software (Xenogen),
in the predetermined areas of incision and implant sites (Fig.
2A). The luminescence signal identified the expression of the
murine VEGFR2 gene 15min after the subcutaneous injection
of luciferin.
The overall analysis of the luminescence results showed that
for all the tested conditions the luminescence signal, at the
incision area was higher than at the implantation sites (Fig. 2B,
C). Nevertheless, the signal at the incisions was considered to
be related to the expected inflammatory process resulting from
the surgical procedure. Therefore, the effect of the different
constructs on the expression of VEGFR2 was analyzed based
on the signal measured at the implantation sites.
The expression of VEGFR2 at the SPCL-WS implantation
sites was comparable ( p > 0.05) to the control (pocket) for all
time points except at the preimplantation time (Fig. 2B). At
this time point, the animals randomly selected for the im-
plantation of SPCL-WS scaffolds showed a higher VEGFR2
expression ( p < 0.05) in comparison to the animals selected
for controls (pockets). Conversely, after implantation, the
two groups of animals showed a similar VEGFR2 expression
at the implant sites for all time points. The luminescence
signal did not vary along the implantation period.
When fibrin sealant was added to the SPCL-WS scaf-
folds, a different profile of VEGFR2 expression was observed
in comparison to the scaffold alone (Fig. 2B). At day 3 of
SPCL-WS +FS implantation, the expression of VEGFR2 was
significantly lower ( p < 0.05), increasing from that day on-
ward to comparable values of the SPCL-WS. Moreover,
the VEGFR2 expression for the SPCL-WS +FS decreased
( p< 0.05) until day 3 and increased from that point reaching
a significantly higher ( p< 0.05) value at day 6 that was
comparable to those detected until day 13 ( p > 0.05).
Higher levels of VEGFR2 expression were detected in the
animals where SPCL-FB scaffolds were implanted in com-
parison to the animals with SPCL-WS before implantation.
The VEGFR2 expression at the SPCL-FB implantation sites
was higher ( p < 0.05) than the control for all the time points
except postimplantation (Fig. 2C). Nonetheless, a significant
increase ( p< 0.05) of the VEGFR2 expression at the SPCL-FB
implantation site was observed from the time point post-
implantation up to day 3. The slight diminished expression
from day 6 onward was not significant ( p > 0.05).
The addition of fibrin sealant to the SPCL-FB scaffolds
induced a lower VEGFR2 expression ( p< 0.05) at days 6 and
9 in comparison to SPCL-FB. However, the preimplant ex-
pression of VEGFR2 was already lower in the animals for
SPCL-FB +FS scaffolds implantation in comparison to the
animals for SPCL-FB implantation ( p < 0.05) (Fig. 2C). De-
spite this, a significant increased ( p< 0.05) expression of
VEGFR2 was observed from the postimplantation time point
to day 3 and 13 of SPCL-FB + FS implantation.
When hASCs were added to the SPCL-WS+ FS construct,
the luminescence pattern detected at the implantation sites
did not change in comparison to the constructs composed of
SPCL-WS and fibrin sealant. In addition, along the time of
SPCL-WS + FS +hASCs implantation the VEGFR2 expression
at the implant sites was similar, significantly decreasing
( p< 0.05) from pre- to postimplantation (Fig. 2C).
Similarly to what was observed for the SPCL-WS + FS, the
addition of hASCs to the SPCL-FB +FS construct did not
induced significant differences in the detected luminescence
at the implantation sites (Fig. 2C). Along the implantation
period, a statistically significant increase of the detected
signal was observed until day 3 ( p < 0.05) (Fig. 2C).
The addition of either VEGF or FGF-2 to the SPCL-
WS + FS + hASCs constructs did not change the pattern of
VEGFR2 expression as compared to the construct with fi-
brin sealant and hASCs (Fig. 2B). The expression of
VEGFR2 at the SPCL-WS + FS + hASCs +VEGF implantation
site significantly increased ( p < 0.05) from day 9 to 13
reaching a significantly higher value ( p < 0.05) in compari-
son to the postimplantation time point. Similar results were
obtained along the time of implantation of the SPCL-WS +
FS + hASCs + FGF-2 constructs, although the increasing of
the luminescence signal was not significant from day 9 to 13
(Fig. 2B).
Table 2. Forward and Reverse Sequences of the Genes Detected
by Reverse Transcriptase–Polymerase Chain Reaction
Function Gene Sequences Tm (C) bp
Vascularization VEGF-a Forward: CCGAAACCATGAACTTTCT 55.19
Reverse: CGTTCGTTTAACTCAAGCTG 56.31 604
VEGFR1 Forward: GAGGGATAACAGGCAATTC 54.59
Reverse: CCCAGCAAGATCGTATAGTC 54.91 960
Inflammation IL-4 Forward: TCATCCTGCTCTTCTTTCTC 54.67
Reverse: GATGTGGACTTGGACTCATT 54.82 325
IFN-c Forward: CTACCTTCTTCAGCAACAGC 55.36
Reverse: TGTAGACATCTCCTCCCATC 54.92 568
TNF-a Forward: GTCTCAGCCTCTTCTCATTC 54.03
Reverse: CAGAGTAAAGGGGTCAGAG 54.57 654
VEGFR1, vascular endothelial growth factor receptor-1; TNF-a, tumor necrosis factor-alpha; IL-4, interleukin 4; IFN-g, interferon-gamma.
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In what concerns the incorporation of growth factors
(VEGF and FGF-2) into the SPCL-FB + FS +hASCs constructs,
like for the SPCL-WS+ FS +hASCs constructs, the expression
of VEGFR2 did not change, except for the lower signal de-
tected in the animals implanted with the SPCL-FB + FS +
hASCs + FGF-2 postimplantation. However, a significant in-
crease ( p< 0.05) was observed between the implantation day
and the end of observation, day 13, for SPCL-FB + FS +
hASCs constructs with both growth factors (Fig. 2C).
The addition of the growth factors (VEGF and FGF-2) to
the SPCL-WS-based constructs induced a similar profile of
VEGFR2 expression in both constructs. From the implanta-
tion day until day 3, a decrease on the luminescence signal
was observed, after a significant increase ( p< 0.05) until the
end point of the experiment (day 13). The overall data dem-
onstrated that the expression of VEGFR2 was promoted after
VEGF or FGF-2 incorporation on SPLC-WS-based constructs.
Inflammation and vascularization. At the end of the ex-
periment (2 weeks), the subcutaneously implanted TE con-
structs were explanted, along with the surrounding tissue,
for histological and molecular biology analysis.
In terms of inflammatory reaction to the implantation of
the TE constructs, the histological analysis allowed to ob-
serve that for all tested conditions neither the addition of
hASCs or fibrin sealant from human origin, nor the release of
VEGF or FGF-2 from the implanted constructs to the im-
plantation site, elicited an exuberant inflammatory or rejec-
tion response from the transgenic VEGFR2-luc mice (Fig. 3).
The observed inflammatory reaction can be considered of
moderate intensity and characterized by the presence of
some polymorphonuclear neutrophils (PMNs), mononuclear
cells (lymphocytes and macrophages), and some foreign
body giant cells (Fig. 3). These observations were com-
plemented with the RT-PCR analysis that confirmed the ex-
pression of interleukin (IL)-4 and interferon-gamma (IFN-g),
two inflammatory cytokines, for all the tested conditions
except when only the SPCL scaffolds were implanted (Fig. 4).
In addition, tumor necrosis factor-alpha (TNF-a) expression
was detected in all the test groups except the controls in
which IL-4 and IFN-g were also not detected. In fact, in the
control animals a residual inflammatory infiltrate, compris-
ing PMNs and mononuclear cells was found as a reaction to
the created pockets (Fig. 3).
Concerning the vascularization specific markers, all the
tested conditions, including the controls, expressed VEGF.
Contrarily, VEGFR1 expression was only detected in the
tissues where the SPCL-WS+ FS +hASCs +FGF-2, the SPCL-
FB +FS +hASCs +VEGF, and the SPCL-FB +FS +hASCs
constructs were implanted (Fig. 4). In the groups, SPCL-WS-
FS-ASC-VEGF and SPCL-WS-FS-ASC-FGF the MVC was
significantly higher than in the pocket (Table 3). These results
were confirmed using CD31 and von Willebrand Factor
staining. Many endothelial cells, as characterized by these
two markers, were seen in SPCL-WS-FS-ASC-VEGF and
SPCL-WS-FS-ASC-FGF. These built mature vessels and also
microvessels could be identified (Figs. 5 and Fig. 6).
Discussion
Tissue engineering has been facing an impairment on the
development of suitable constructs, which is to promote the
concomitant ingrowth of new blood vessels as the tissue is
healing and remodeling. Considerable steps have been taken
toward new advances by coculturing endothelial cells and
osteoblasts11,14,39 or stem cells within 3D matrices16 or by
controlled release relevant growth factors from those struc-
tures21,22 that can simultaneously support cell growth and
tissue ingrowth.4,40 Extensively studied starch-based scaf-
folds have shown great potential for bone tissue engineering,
not only demonstrated by their capacity to support osteo-
genic differentiation41 and further bone matrix deposition/
mineralization,12 but also to bear the formation of vascular-
like structures both in vitro14,42,43 and in vivo.11 Based on
these, the main aim of this work was to assemble an im-
proved bone TE construct, composed by SPCL-based scaf-
folds, angiogenic growth factors (VEGF and FGF-2), and
hASCs, and to assess the effect of each element over the
expression of several neovascularization-related markers.
A major concern with TE constructs is the fate and
consequent role of the cells composing the construct after
transplantation. Cell transfection by lipofection has been
shown to be a useful tool to trace cells either in an in vitro
system33,44,45 or in animal models.46,47 An immunosup-
pressed mouse model was used to implant the two types of
SPCL scaffolds seeded with transfected hASCs to conclude
about the effect of the processing methodology over the cell
fate within the host. It was possible to conclude that the two
methodologies used to process the SPCL scaffolds, wet
spinning and fiber bonding, did not induce differences, first
on the adhesion of the seeded ASCs, and then on their mi-
gration after implantation. It was shown that the kinetic
profile of the emitted luminescence by the transfected cells
seeded on the scaffolds was similar to the SPCL-WS and for
the SPCL-FB scaffolds. As the implants were introduced into
the subcutaneous pockets of the nude mice, the transfected
cells started to migrate from the scaffolds and moved to the
dorsum of the animals. This was concluded from the higher
luminescence signal observed in the dorsum area in com-
parison to the implantation areas. This is in accordance with
our previous knowledge, showing the release of ASCs from a
substrate (unpublished data). The scaffold can thus, be used
as a means to implant the cells at the site of interest. The
migrating cells can give cues to the surrounding tissue for
vascularization and bone formation. Thus, in a clinical set-
ting this may accelerate bone healing by increasing both
vascularization and possibly osteogenesis. Nevertheless, the
presence of the scaffold at the implant site may interfere with
the luminescence signal detected by the software. Therefore,
it may be speculated that the luminescence signal detected at
the implantation sites was altered by the presence of the
SPCL scaffolds. The increased signal observed from day 2 up
to day 6 after implantation, and the similar kinetics profile
for the implantation sites and for the dorsum of the animals,
are indicative of cell proliferation in both sites. The decrease
on the emitted signal observed from day 6 onward indicates
that the cells are losing the plasmid, which is also in accor-
dance with previous indications (unpublished data).
A VEGFR2-luc transgenic mouse model previously es-
tablished,36 using the murine VEGFR2 promoter to direct
the expression of the luciferase reporter, was used to assess
the expression of VEGFR2 under the studied conditions. It
is well reported that VEGFR2 mediates most of the mito-
genic, cell survival, and vascular permeability effects of
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FIG. 3. Micrographs obtained from the TE constructs and surrounding tissue explanted 13 days after implantation in the
transgenic VEGFR2-LUC mice. SPCL-WS +FS +ASCs, SPCL-FB + FS +ASCs, SPCL-FB + FS +ASCs +VEGF, SPCL-FB + FS +
ASCs +FGF-2 and SPCL-FB + FS with lower magnification of 12.5 · and higher magnification of 200· ; SPCL-WS + FS +
ASCs +VEGF, SPCL-WS+ FS +ASCs + FGF-2, SPCL-WS + FS, SPCL-WS, SPCL-FB and Pocket (control) with lower magnifi-
cation of 12.5 · and higher magnification of 100· . ASC, adipose-derived stem cells; FGF, fibroblast growth factor. Color
images available online at www.liebertpub.com/tea
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VEGF.48,49 Moreover, as VEGFR2 plays an important role in
many aspects of blood vessel growth, an in vivo monitor-
ing of the VEGFR2 gene expression, with noninvasive tech-
niques was found useful to achieve its real time function in
angiogenesis.50
While SPCL scaffolds support the formation of vascular-
like structures,11,42,43 and seeded with bone marrow mesen-
chymal cells have clearly proved to be suitable for bone TE
applications,7,12,41 the potential of hASCs together with these
materials was still to be addressed. The influence of hASCs
seeded onto the SPCL scaffolds, as well as the incorpora-
tion and subsequent delivery of VEGF and FGF-2, in vas-
cularization/angiogenesis was addressed by monitoring the
VEGFR2 expression using the VEGFR2-luc transgenic mouse
model and by assessing the induction of healing mediators.
As luciferase measurement is a very sensitive method a large
spread in an in vivo system can be expected. Moreover, it is
an individual measurement on each mouse and the position
of the mouse may also influence the number of photons
measured. Furthermore, the constructs are slowly declining
and disappearing from the cells as described in the materials
and methods sections. However, thorough statistical analysis
was performed and we feel that the difference is important.
Proinflammatory cytokines, such as IL-6, IL-8, and TNF-a,
and various growth factors, like VEGF, are necessary for
healing.51 Additionally, VEGF is also determinant for pro-
genitor endothelial cells recruitment and for promoting an-
giogenesis.52,53 Thereby, it would be important for clinical
application as angiogenesis is increased and thus, may en-
sure survival of transplanted cells and of the whole graft.
The herein presented results show that all conditions es-
tablished with the assembled bone TE constructs induced the
expression of the VEGF gene by the tissues hosting the im-
plants, as well as the control tissues where nothing was
implanted. Although the control animals had no implant, the
creation of the pocket induced an inflammatory reaction,
exactly as in the animals where the implants were placed. In
both situations, the host tissue had to recover from the injury
and restore the damaged tissue and associated vasculature.
FIG. 4. Electrophoresis gels of the PCR results showing the expression of inflammation, neovascularization, and osteogenic
potential specific genes. The gene expression was assessed at the end time point of the experiment (2 weeks), on the
implanted TE construct and respective surrounding tissue. PCR, polymerase chain reaction.
Table 3. Microvessel Count in Histological
Specimens (Mean – Standard Deviation)
Group Vessel count
Spcl-ws 55.2 – 14.5
Spcl-ws-fs-asc 58.4 – 23.1
Spcl-ws-fs 45.8 – 25.2
Spcl-ws-fs-asc-vegf 77.9 – 24.8a
Spcl-ws-fs-asc-fgf2 81.3 – 32.9a
Pocket 32.2 – 19.7
ap< 0.05.
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In this sense, it is possible to substantiate the expression of
VEGF in all conditions, including the controls.
At the molecular level it was shown that, when the SPCL
scaffolds (SPCL-WS and SPCL-FB) were implanted as sim-
ple materials, they did not elicit the expression of the spe-
cific markers of inflammation, IL-4 and IFN-g. In addition,
VEGF but not VEGFR1 expression was also detected after
SPCL-WS and SPCL-FB implantation. The histological
analysis also confirmed a residual inflammatory infiltrate in
the vicinity of the SPCL scaffolds. For both short- and long-
term subcutaneous implantations of SPCL-WS and SPCL-
FB scaffolds, no severe inflammatory reaction has been
previously observed.54 All together, these results demon-
strate that SPCL possess a low inflammatory potential very
unusual for a biodegradable scaffold, and that the detected
VEGFR2 expression in the luminescence experiments are
certainly related to the produced VEGF since VEGFR2 is
the major receptor for that growth factor.55 Although it
has been reported that inflammatory cells, namely macro-
phages, express VEGFR1 in response to VEGF stimula-
tion,55–57 in this study, it was not possible to establish this
correlation.
An interesting finding was the lower expression of the
VEGFR2 in the SPCL-FB + FS in comparison with the SPCL-
FB scaffold. This may be due to the incorporation of fibrin
sealant which might be minimizing an eventual physical
aggression of the subcutaneous tissue and consequent in-
flammation with the expression of VEGF receptors. Never-
theless, the histological features showed only a moderate
inflammatory reaction for both conditions. Additionally,
the molecular analysis showed that the introduction of fi-
brin sealant, ASCs, and growth factors enhanced the ex-
pression of inflammatory mediators (IL-4, TNF-a, IFN-g)
compared with scaffolds alone.
When the hASCs were added, the expression of VEGFR2
showed to be similar to the SCPL-based constructs with fi-
brin sealant. However, at the molecular level, while the
VEGF expression was detected for all the conditions, the
expression of VEGFR1 was detected for the SPCL-FB + FS +
hASCs construct, but not for the SPCL-WS+ FS +hASCs. A
possible explanation for this finding may be the differences
on the SPCL-FB and SPCL-WS scaffolds, regarding the
properties of the fibers. Roughness and fiber’s diameter have
been shown to influence tissue response58,59; thus, the fact
FIG. 5. (A) Pocket, (B)
SPCL-WS, (C) SPCL-WS-FS,
(D) SPCL-WS-FS-ASC-FGF-2,
(E) SPCL-WS-FS-ASC-VEGF.
Staining for CD31 shows
endothelial and endothelial
precursor cells (arrows).
Peroxide coupled CD31
antibody was visualized
using diaminobenzidine and
is shown as a brown color.
The scale bar represents
100 mm. Color images
available online at www
.liebertpub.com/tea
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that SPCL-WS has thinner and smoother fibers might be af-
fecting the VEGFR2 expression in the tissue directly con-
tacting with the scaffold. Moreover, despite the induced
expression of the proinflammatory cytokines IL-4, IFN-g, and
TNF-a by the hASCs-assembled constructs, the histological
analysis does not corroborate the existence of a persistent
acute inflammation.
VEGF and its receptors, among others VEGFR1, are
important factors in the establishment, progression, and
maturation of new blood vessels.60–63 During normal
wound healing64 VEGF expression correlates temporally
and spatially with the proliferation of new blood vessels.65
Additionally to VEGF, FGFs are homeostatic factors with
function in tissue repair and response to injury in adult
organisms.66
While the incorporation and subsequent release of both
VEGF and FGF-2 from the SPCL-WS did not induce a sig-
nificant effect over VEGFR2 expression, the expression of this
receptor was significantly decreased in the SPCL-FB + FS +
hASCs +VEGF and SPCL-FB + FS +hASCs + FGF-2 implan-
tation sites in comparison to unloaded constructs.
The high expression of VEGFR2 at the incision areas in all
tested conditions was not an expected result. Nevertheless, it
is plausible to detect these high values of luminescence since
VEGFR2 is a factor involved on the ongoing inflammatory
process and related with healing of the injured region.64
Additionally, the expression of VEGFR2 translates the vas-
cularization status at the implantation sites.55
In summary, we have shown that induction of angiogenic
markers occur. Thus, some of our combinations are impor-
tant inductors. This implies that such combinations should
be used rather than others where no induction of these
markers was observed. The next step will be to use exactly
these constructs in models of bone regeneration to investi-
gate whether they perform better due to their enhanced an-
giongenic potential than other not equally angiogenic
constructs.
Conclusions
Taken together, the presented results show that; (1) the
starch-based scaffolds obtained by different processing
FIG. 6. (A) Pocket, (B)
SPCL-WS, (C) SPCL-WS-FS,
(D) SPCL-WS-FS-ASC-FGF-2,
(E) SPCL-WS-FS-ASC-VEGF.
Staining for von Willebrand
Factor shows endothelial and
endothelial precursor cells
(arrows). Peroxide coupled
von Willebrand Factor
antibody was visualized
using diaminobenzidine and
is shown as a brown color.
The scale bar represents
100 mm. Color images
available online at www
.liebertpub.com/tea
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methodologies are suitable supports for hASCs; (2) the
starch-based scaffolds may be used to assemble a complex
TE construct composed by a fibrin sealant, hASCs, and
growth factors (VEGF and FGF-2); (3) after 2 weeks of im-
plantation, the assembled TE constructs did not elicit an
adverse host reaction, showing a moderate inflammatory
response typically observed for implanted devices and; (4)
the addition of VEGF and FGF-2 to the TE construct showed
to be favorable, at the molecular level, for the expression of
neovascularization specific markers.
In summary, the overall results indicate that the com-
bination of SPCL-WS with fibrin sealant, hASCs, VEGF, or
FGF-2 seems to be the TE construct with promising fea-
tures for vascularization of newly formed tissue and
thus, may be considered for further studies for bone TE
applications.
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